Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma.
Guglielmelli
Tommasina
T
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy. tguglielmelli@libero.it
Capella
Sara
S
Saglio
Giuseppe
G
D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000517:prevention & control*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D013792:Thalidomide; D003907:Dexamethasone